文献速递肿瘤 PET/CT核素与放射性配体治疗

从实验室到临床:Bad Berka在首次人体研究中的诊疗一体化经验

From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
PubMed 文献 · Semin Nucl Med · 2019-07-06

本文综述了Bad Berka在新型放射性药物首次人体研究方面的经验,涵盖前列腺特异性膜抗原配体、胃泌素释放肽受体、神经降压素受体1配体、新型SSTR靶向肽及非肽类、骨靶向放射性药物,并简要讨论了225Ac、64Cu、44Sc、152Tb/161Tb等新放射性同位素,展示了从基础科学到临床精准肿瘤学的发展。

要点

  • 诊疗一体化在核医学中旨在识别肿瘤分子靶点并选择最佳配体与放射性核素进行个体化管理。
  • 68Ga标记肽类SSTR靶向PET/CT联合177Lu/90Y标记SSTR激动剂PRRT在神经内分泌肿瘤管理中取得成功。
  • Bad Berka经验涵盖PSMA配体、GRPR、NTSR1配体、新型SSTR靶向肽及骨靶向药物的首次人体研究。

核心结论

  • 诊疗一体化范式假设诊断测试结果能精确判断个体是否可能从特定治疗中获益。
  • 68Ga标记肽类SSTR靶向PET/CT后接177Lu和90Y标记SSTR激动剂PRRT在神经内分泌肿瘤管理中显示显著成功,并为其他诊疗一体化适应症铺平道路。

研究设计与样本

  • 本文为综述,聚焦Bad Berka在新型放射性药物首次人体研究中的经验。

主要发现

  • Bad Berka经验涉及前列腺特异性膜抗原配体、胃泌素释放肽受体、神经降压素受体1配体、新型SSTR靶向肽及非肽类、骨靶向放射性药物的首次人体研究。
  • 简要讨论了锕(225Ac)、铜(64Cu)、钪(44Sc)、铽(152Tb/161Tb)等新放射性同位素。

临床怎么用

  • 诊疗一体化通过诊断工具识别肿瘤分子靶点,选择最佳配体与放射性核素进行个性化管理并监测治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision oncology is being driven by rapid advances in novel diagnostics and therapeutic interventions, with treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations. Inherent in the theranostics paradigm is the assumption that diagnostic test results can precisely determine whether an individual is likely to benefit from a specific treatment. As part and integral in the current era of precision oncology, theranostics in the context of nuclear medicine aims to identify the appropriate molecular targets in neoplasms (diagnostic tool), so that the optimal ligands and radionuclides (therapeutic tool) with favorable labeling chemistry can be selected for personalized management of a specific disease, taking into consideration the specific patient, and subsequently monitor treatment response. Over the past two decades, the use of gallium-68 labeled peptides for somatostatin receptor (SSTR)-targeted PET/CT (or PET/MRI) imaging followed by lutetium-177 and yttrium-90 labeled SSTR-agonist for peptide receptor radionuclide therapy has demonstrated remarkable success in the management of neuroendocrine neoplasms, and paved the way to other indications of theranostics. Rapid advances are being made in the development of other peptide-based radiopharmaceuticals, small molecular-weight ligands and with newer radioisotopes with more favorable kinetics, potentially useful for theranostics strategies for the clinical application. The present review features the Bad Berka experience with first-in-human studies of new radiopharmaceuticals, for example, prostate-specific membrane antigen ligand, gastrin-releasing peptide receptor, neurotensin receptor 1 ligand, novel SSTR-targeting peptides and nonpeptide, and bone-seeking radiopharmaceuticals. Also new radioisotopes, for example, actinium (225Ac), copper (64Cu), scandium (44Sc), and terbium (152Tb/161Tb) will be discussed briefly demonstrating the development from basic science to precision oncology in the clinical setting.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhang J, Singh A, Kulkarni HR, et al. From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies. Semin Nucl Med. 2019. PMID: 31470935. doi:10.1053/j.semnuclmed.2019.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。